Dominik Feuerbach

This inventor holds 1 USPTO granted patent. Top assignee: Novartis Ag. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Dominik Feuerbach. Retrieved from https://idiyas.com/inventor/dominik-feuerbach-gflpod5m

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 1.0


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Dominik Feuerbach: Innovator in Antibody Stabilization

Introduction

Dominik Feuerbach is a notable inventor recognized for his contributions to the field of biotechnology. He is currently associated with Novartis AG, a leading global healthcare company. His work primarily focuses on the development of innovative solutions in the realm of antibodies.

Latest Patents

Dominik Feuerbach holds a patent for TREM2 Stabilizing Antibodies. This patent represents a significant advancement in the stabilization of antibodies, which can have profound implications for therapeutic applications.

Career Highlights

Throughout his career, Dominik has demonstrated a commitment to scientific excellence and innovation. His work at Novartis AG has positioned him as a key player in the biotechnology sector, contributing to the development of cutting-edge medical solutions.

Collaborations

Dominik collaborates with Fabrizio Gasparini, leveraging their combined expertise to drive forward innovative projects within their organization.

Conclusion

Dominik Feuerbach's contributions to the field of biotechnology, particularly through his patent on TREM2 Stabilizing Antibodies, highlight his role as an influential inventor. His ongoing work at Novartis AG continues to pave the way for advancements in medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…